Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $33 and keeps a Buy rating on the shares following the Q4 report. The firm continues to view 2026 as an important year for bexobrutideg as management executes on two registrational trials and additional Phase 1 updates, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
- Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler
- Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
- Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
- Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)